Observational studyAnnals of African medicine2026
Effect of Addition of Saroglitazar to Lifestyle Modifications in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Observational Study.
Observational study in Annals of African medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNonalcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder with significant health implications. This study aims to evaluate the effect of adding Saroglitazar to lifestyle modifications in improving NAFLD-related parameters compared to lifestyle modifications alone. METHODOLOGY: A prospective observational study was conducted at the Outpatient Department of Gastroenterology, M. S. Ramaiah Hospitals, including patients diagnosed with NAFLD. Patients were divided into two groups: Group 1 received lifestyle modification counseling, and Group 2 received Saroglitazar 4 mg OD in addition to lifestyle modification counseling for 12 weeks. Liver function tests and ultrasonographic findings were assessed at baseline and after 12 weeks.
resultsA statistically significant improvement ( P = 0.02) in alanine transaminase (ALT) levels was observed within the treatment Group 2, along with a trend of improvement in aspartate transaminase (AST) levels ( P = 0.07). However, no significant difference in AST and ALT levels was found between the groups. Ultrasonographic improvements were noted in few patients receiving Saroglitazar, and the drug was well tolerated, with minor adverse events such as nausea and fatigue.
conclusionsThe addition of Saroglitazar to lifestyle modifications showed a beneficial effect in improving NAFLD-related parameters over 12 weeks compared to lifestyle modifications alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.